

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)

FORM PTO-1449

ARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE

OCO1000KQ APPLICANT:

SERIAL NO.: 09/904,263

Rybak et al.

FILING DATE: July 12, 2001

ATTY. DOCKET NO.:

GROUP: 1642

U.S. PATENT DOCUMENTS

*EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS		FILING DATE IF APPROPRIATE	15
AUG	ĀĀ	5,985,263	11/16/99	Lee et al.	424	85.2	7.1110	* 13
100	AB	5,951,974	09/14/99	Gilbert et al.	424	85.7		
	AC	5,908,621	06/01/99	Glue et al.	#24	85.7		
	AD	4,766,106	08/23/88	Katre et al.	514	12		
	ΑE	5,776,897	07/07/98	Lewis et al.	514	12		
	AF	5,766,582	06/16/98	Yuen et al.	424	85.7		
	AG	5,762,923	06/09/98	Gross et al.	424	85.7	<b>RECEIV</b>	ED
	АН	5,382,427	01/17/95	Plunkett et al.	424	03.2	ITECLIV	LU
	Al	4,917,888	04/17/90	Katre et al.	424	85.91		
	AJ	4,897,471	01/30/90	Stabinsky /	536	27	MAR 1 0 20	03
	AK	4,695,623	09/22/87	Stabinsky /	530	351		
	AL	4,530,901	07/23/85	Weissmann /	435	70 IE	CH CENTER 1	600/290
	АМ	4,492,537	01/08/85	Awerkamp /	417	404		700,200
	CE	5,711,944	1/27/98	Gilbert etal.	424	85.7		
	CF	5,766,897	06/16/98	Braxton /	435	172.1		
	CG	6,362,162 B1	03/26/02	Rybak et al.	514	2		
	СН	2001/0053548 A1	08/09/01	Rybak et al.	435	367		l

FOREIGNIPATENT DOCUMENTS

	I	DOCUMENT	DATE V	COUNTRY	CLASS	SUB-	TRANS	<u> ATION</u>
		NUMBER				CLASS	YES	NO
AM	AN	0 236 987 B1	12/28/94	EPO				
1	AO	0 809 996 A2	12/03/97	EPO				
	AP	0 593 868 A1	04/27/94	EPO				
	AQ	WO 99/48535	30/09/99	WIPO				
	AR	0 510 356 A1	10/28/92	EPO				<u> </u>
- i	CD	WO95/13090 /	05/18/95	WIPO				
<u> </u>	CL	WO98/48840 /	05/11/98	WIPO			<u> </u>	
					–			

	OT	HER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AUN	AS	Kantarjian et al., "Treatment of Chronic Myelogenous Leukemia: Current Status and Investigational Options," Blood 87:8 pp. 3069-3081, April 15, 1996
AT		Hehlman et al., "Randomized Comparison of Interferon-α With Busulfan and Hydroxyurea in Chromic Myelogenous Leukemia," Blood <b>84</b> :12 pp. 4064-4077, December 15, 1994
AU		Kantarjian et al., "Chronic Myelogenous Leukemia: A Concise Update," Blood 82:3 pp. 691-703, August 1, 1993
	AV	Nicolaou et al., "Total Synthesis of Taxol. 1. Retrosynthesis, Degradation, and Reconstitution," J. Am. Chem. Soc. 117 pp. 624-633, 1995
ALH	AW	Hasford, et al "Interferon- $\alpha$ and Hydroxyurea in Early Chronic Myeloid Leukemia: A Comparative Analysis of the Italian and German Chronic Myeloid Leukemia Trials With Interferon- $\alpha$ ," Blood 87(12):5384-5391 (1996).
M/I AX		Ozer et al., "Prolonged Subcutaneous Administration of Recombinant α2b Interferon in Patients with Previously Untreated Philadelphia Chromosome-Positive Chronic-Phase Chronic Myelogenous Leukenia: Effect on Remission Duration and Survival: Cancer and Leukemia Group B Study 8583," Blook 82:10 pp. 2975-2984, November 15, 1993
AY		Ohnishi et al., A Randomized Trial Comparing Interferon-α With Busulfan for Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase," Blood <b>86</b> :3 pp. 906-916, August 1, 1995

anne L. Hollmain

5/17/2003

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.: OCO1000KQ

SERIAL NO.: RECEIVED

MAR 1 d 2003

Rybak et al. FILING DATE: July 12, 2001

APPLICANT:

GROUP: TECH CENTER 1600/2!

AZ Creagon et al., "Randomized, Surgical Adjuvant Clinical Trial of Necombinant Signation Maignant Melanoma," Journal of Clinical Oncology, 13:1/jpp. 2776-2783 November 1995  BA Bergmann et al., "Daily Alternating Administration of High-Dose Alph-2b-Interferon and Interleukin-2 Bolus Infusion in Metastatic Renal Cell Cancer," Cancer 72:5, 6p. 1736-1742 September 1, 1993  BB Umeda et al., "Phase II Study of Alpha Interferon on Renal Cell Carcinoma," Cancer 58:1231-1235, September 15, 1986  BC Sokal et al., "Preferential Inhibition by Cytarabine of CFU-GM From Patients With Chronic Granulocytic Leukemia," Cancer 59:197-202, January 1, 1987  BD Fleming et al., "One-Sample Multiple! Testing Procedure for Phase II Clinical Trials," Biometrics 38:143-151 March 1982  BE Rosenberg, et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989  BF Kantarjian et al., "Preforaged Survical in Chronic Myelogenous Leukemia after Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Interhal Myelogenous Leukemia, "Annals of Interhal Myelogenous Leukemia," Annals of Interhal Myelogenous Leukemia," Annals of Interhal Myelogenous Leukemia, "Annals of Interhal Myelogenous Leukemia," The New England Journal of Medicine," 3374: pp. 270-271, July 24, 1997  BI Guilhot, et al., "Interferon Alfa-2b Complined with Cytarabine Versus Interferon Alfa-2a as Compared with Conventional, Cytemotherapy for the Treatment of Chronic Myelogenous Leukemia," The New England Journal of Medicine," 330:12 pp. 820-825, March 24, 1994  BL Atzpodien et al., "Multiprical From Alfa-2b Adjuvant Interferon Alfa-2h (Pronic Myelographical Cinicial Oncology, 14: 1 pp./7-17, January 1996  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Interferon Suchemia," Neminglandicies," The Lancet, 343:913-914 April 9, 1994  BM Atzpodien et al., "Progensylvin Such Progensive Metastatic Re			Alfo On in
BA Bergmann et al., "Daily Alternating Administration of High-Dose Alph-2b-Interferon and Interleukin-2 Bolus Infusion in Metastatic Renal Cell Cancer," Cancer 72:5, ρp. 1735-1742 September 1, 1993 BB Umeda et al., "Phase II Study of Alpha Interferon on Renal Cell Carcinoma," Cancer 58:1231-1235, September 15, 1986 BC Sokal et al., "Preferential Inhibition by Cytarabine of CFU-GM From Patients With Chronic Granulocytic Leukemia," Cancer 59:197-202, January 1, 1987 BD Fleming et al., "One-Sample Multiplel Testing Procedure for Phase II Clinical Trials," Biometrics 38:143-151 March 1982 BE Rosenberg, et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients." Ann. Sung. 210:4 pp. 474-485. 1989 BF Kantarjian et al., "Prolonged Survical in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α. Therapy." Ann Intern Med. 122:254-261. 1995 BG Taipaz et al., "Interferon-Alpha Produces Suskinged Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internal Myelogenous Leukemia and Internal Myelogenous Leukemia." Annals of Internal Myelogenous Leukemia ("Annals of Internal Myelogenous Leukemia," Annals of Internal Myelogenous Leukemia, "The New England Journal of Medicine," 337:4, pp. 270-271. July 24, 7997 BJ Guilhot, et al., "Interferon Alfa-20 Carcinomys," The New England Journal of Medicine," 337:4, pp. 270-271. July 24, 7997 BJ Guilhot, et al., "Interferon Alfa-20 Carcinomys," The New England Journal of Medicine," 337:4, pp. 223-229 BK The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "The New England Journal of Medicine," 337:4, pp. 223-229 BK The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Interferon Alfa-20 a Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995 BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interfereklin-2 and Interferon Alfa-20 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology,	^	AZ	Creagon et al., "Randomized, Surgical Adjuvant Clinical Trial of Recombinant Interferon Alfa-2a in
BA Bergmann et al., "Dally Alternating Administrationn of High-Dose Alph-2b-Intefferon and Interleukin-2 Bolus Infusion in Metastatic Renal Cell Cancer," Cancer 72:5, 6p. 1735-1742. September 1, 1993  BB Umeda et al., "Phase II Study of Alpha Interferon on Renal Cell Carcinoma," Cancer 58:1231-1235. September 15, 1986  BC Sokal et al., "Preferential Inhibition by Cytarabine of CPU-GM Front Patients With Chronic Granulocytic Leukemia," Cancer 59:197-202, January 1, 1987  BD Fleming et al., "One-Sample Multiple! Testing Procedure for Phase II Clinical Trials," Biometrics 38:143-151 March 1992  BE Rosenberg, et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989  BF Kantarjian et al., "Prolonged Survical in Chronic Myelogenouos Leukemia after Cytogenetic Responses to Interferon-Alpha Produces Susjáned Cytogenetic Responses in Chronic Myelogenouous Leukemia," Annals of Interhal Myelogenouos Leukemia after Cytogenetic Responses in Chronic Myelogenouous Leukemia," Annals of Interhal Myelogenetics, 141-7, 1911  BH Negrier et al., "Interferon-Alpha Produces Susjáned Cytogenetic Responses in Chronic Myelogenouous Leukemia," Annals of Interhal Myelogenetics, 141-7, 1911, 1991  BH Negrier et al., "Interferon-Alpha Produces Susjáned Cytogenetic Responses in Chronic Myelogenouous Leukemia," Annals of Interhal Myelogenouous Leukemia, "Annals of Interhal Myelogenous Leukemia," Annals of Interhal Myelogenous Leukemia," Annals of Interhal Myelogenous Leukemia, "The New England Journal of Medicine," 337-4, pp. 270-271, July 24, 1994  BJ Guilhot, et al., "Interferon Alfa-20 admined with Cytarabine Versus Interferon Alfa-20 as September 1995  BJ Guilhot, et al., "Interferon Marcha 20 admined with Cytarabine Versus Interferon Alfa-20 as Compared with Conventional Cytemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, 337-4, pp. 223-229  BK The Italian Cooperative Study Graph On Chronic Myeloid Leukemia, "The	ANH		Selected Patients With Malignant Melanoma," Journal of Clinical Oncology, 13:13/5p. 2776-2783
Intereukin-2 Bolus Infusion in Metastatic Renal Cell Cancer," Cancer 72:5, δp. 1735-1742   September 1, 1993   Umeda et al., "Phase II Study of Alpha Interferon on Renal Cell Carcinoma," Cancer 58:1231-1235, September 15, 1986   BC   Sokal et al., "Preferential! Inhibition by Cytarabine of CFU-GM From Patients With Chronic Caramidocytic Leukemia," Cancer 59:197-202, January 1, 1987   BD   Fleming et al., "Cone-Sample Multiple! Testing Procedure for Phase II Clinical Triats," Biometrics 31:143-151 March 1982   BE   Rosenberg, et al., "Experience with the Use of High-Dose Interieukin-2 in the Treatment of 652   Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989   BF Kantarjian et al., "Interferon Agreement of CFU-GM Expenses in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α Therapy," Ann Intern Med/122:254-261, 1995   BG   Talpaz et al., "Interferon-Alpha Produces Suskinged Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internal Medicine, 114:7 April 1, 1991   BH   Negrier et al., "Interiors Regimen of Cytokhes with Interieukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinomas", Journal of Immunotherapy, 17:62-68 1995   BI   Goldman, "Optimizing Treatment for Cytokhes With Interieukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinomas", Journal of Medicine, 337:4, pp. 270-271, July 24, /997   BK   The Italian Cooperative Study Group on Chronic Myeloid Leukemia," The New England Journal of Medicine, 337:4, pp. 270-271, July 24, /997   BK   The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "The Foren Alfa-2 be arbitrotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, 330:12 pp. 497-501 February 1995   BK   Alzyodien et al., "Melhistituli/onal Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995   BK   Kirkwood et al., "Interf	1 10		November 1995
Intereukin-2 Bolus Infusion in Metastatic Renal Cell Cancer," Cancer 72:5, δp. 1735-1742   September 1, 1993   Umeda et al., "Phase II Study of Alpha Interferon on Renal Cell Carcinoma," Cancer 58:1231-1235, September 15, 1986   BC   Sokal et al., "Preferential! Inhibition by Cytarabine of CFU-GM From Patients With Chronic Caramidocytic Leukemia," Cancer 59:197-202, January 1, 1987   BD   Fleming et al., "Cone-Sample Multiple! Testing Procedure for Phase II Clinical Triats," Biometrics 31:143-151 March 1982   BE   Rosenberg, et al., "Experience with the Use of High-Dose Interieukin-2 in the Treatment of 652   Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989   BF Kantarjian et al., "Interferon Agreement of CFU-GM Expenses in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α Therapy," Ann Intern Med/122:254-261, 1995   BG   Talpaz et al., "Interferon-Alpha Produces Suskinged Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internal Medicine, 114:7 April 1, 1991   BH   Negrier et al., "Interiors Regimen of Cytokhes with Interieukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinomas", Journal of Immunotherapy, 17:62-68 1995   BI   Goldman, "Optimizing Treatment for Cytokhes With Interieukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinomas", Journal of Medicine, 337:4, pp. 270-271, July 24, /997   BK   The Italian Cooperative Study Group on Chronic Myeloid Leukemia," The New England Journal of Medicine, 337:4, pp. 270-271, July 24, /997   BK   The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "The Foren Alfa-2 be arbitrotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, 330:12 pp. 497-501 February 1995   BK   Alzyodien et al., "Melhistituli/onal Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995   BK   Kirkwood et al., "Interf	1	BA	Bergmann et al., "Daily Alternating Administrationn of High-Dose Alph-2b-Interferon and
Be Umeda et al., "Phase II Study of Alpha Interferon on Renal Cell Carcinoma," Cancer 58:1231-1235, September 15, 1986  BC Sokal et al., "Proferential Inhibition by Cytarabine of CFU-GM From Patients With Chronic Granulocytic Leukemia," Cancer 59:197-202, January 1, 1987  BD Fleming et al., "One-Sample Multiplel Testing Procedure for Phase II Clinical Triats," Biometrics 38:143-151 March 1982  BE Rosenberg, et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989  BF Kantarjian et al., "Prolonged Survical in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α Therapy," Ann Intern Med/122:284-281, 1995  BG Talpaz et al., "Interferon-Alpha Produces Suskinged Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internal Modicine, 1147-7 April 1, 1991  BH Négrier et al., "Interferon-Alpha Produces Suskinged Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internal Modicine, 1147-7 April 1, 1991  BH Négrier et al., "Interferon Alpha Produces Suskinged Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internal Modicine, 1147-7 April 1, 1991  BH Négrier et al., "Interferon Alpha Produces Suskinged Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internal Modicine, 1147-7 April 1, 1991  BJ Guilhot, et al., "Interferon Alpha Produces Suskinged Cytogenetic Responses in Chronic Myelogenous Leukemia," The New England Journal of Medicine, 337-4, pp. 223-229  BK The Italian Cooperative Study Gropp on Chronic Myeloid Leukemia," The New England Journal of Medicine, 330-12 pp. 820-825, March 24, 1994  BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interferon Alfa-2a as Compared with Conventional, Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, 330-12 pp. 820-825, March 24, 1994  BK Alzpodien et al., "Fleropessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 1994-75-	1		Interleukin-2 Bolus Infusion in Metastatic Renal Cell Cancer." Cancer 72:5. op. 1735-1742
BB Umeda et al., "Phase II Study of Alpha Interferon on Renal Cell Carcinoma," Cancer 58:1231-1235, September 15, 1986  BC Sokal et al., "Preferential Inhibition by Cytarabine of CFU-GM From Patients With Chronic Granulocytic Leukemia," Cancer 59:197-202, January 1, 1987  BD Fleming et al., "One-Sample Multiplel Testing Procedure for Phase II Clinical Triats," Biometrics 31:43-151 March 1982  BE Rosenberg, et al., "Experience with the Use of High-Dose Interfeukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989  BF Kantarjian et al., "Prolonged Survicial in Chronic Myelogenouos Leukemia after Cytogenetic Response to Interferon-α Therapy," Ann Intern Med/122:254-261, 1995  BG Talpaz et al., "Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Interhag Myelogenouos Leukemia after Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Interhag Myelogenouos Leukemia after Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Interhag Myelogenouos Leukemia after Cytokinke With Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinomy." Journal of Immunotherapy, 17:62-68 1995  BI Goldman, "Optimizing Treatment for Cytokinke With Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinomy." Journal of Medicine, 337:4 pp. 270-271, July 2a, /997  BJ Guilhot, et al., "Interferon Alfa-2b Cytogenetic With Cytarabine Versus Interferon Alfa-2a as Compared with Conventiola, Cyteriotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Thereforon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BK Alzpodien et al., "Methistitutional Home-Therapy Triat of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clini	1		
September 15, 1986  BC Sokal et al., "Preferentiall Inhibition by Cytarabine of CFU-GM From Patients With Chronic Granulocytic Leukemia," Cancer 59:197-202, January 1, 1987  Fleming et al., "Ches-Sample Multiplet Testing Procedure for Pkáse II Clinical Trials," Biometrics 38:143-151 March 1982  BE Rosenberg, et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. 210-4 pp. 474-485, 1989  BF Kantarjian et al., "Prolonged Survical in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-Alpha Produces Susking Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Interlay Migdicine, 1147-7 April 1, 1991  BG Talpaz et al., "Interferon-Alpha Produces Susking Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Interlay Migdicine, 1147-7 April 1, 1991  BH Négrier et al., "Intersite Replacer of Cytokines with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinomis," Journal of Immunotherapy, 17-52-68 1995  BI Goldman, "Optimizing Treatment for Opticic Myeloid Leukeemia," The New England Journal of Myelogenous Leukemia," The New England Journal of Myeloid Leukemia, "Interferon Alfa-2 be Spriphined with Cytarabine Versus Interferon Alfa-2 as Compared with Conventional Chlemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Gropfy on Chronic Myeloid Leukemia, "The New England Journal of Medicine," 330:12 pp. 820-825, March 24, 1994  BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 be Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 13:2 pp	<del></del>	BB.	Umada et al. "Phase II Study of Alpha Interferon on Renal Cell Carcinoma." Cancer 58:1231-1235.
BC Sokal et al., "Preferential! Inhibition by Cytarabine of CFU-GM Front Patients With Chronic Granulocytic Leukemia," Cancer Sei 197-202, January 1, 1987  BD Fleming et al., "One-Sample Multiple! Testing Procedure for Pháse II Clinical Trials," Biometrics 38:143-151 factor 1982  BE Rosenberg, et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989  BF Kantarjian et al., "Prolonged Survicial in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α Therapy," Ann Intern Med. 122:254-261, 1995  BG Talpaz et al., "Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internat Medicine, 114:7 April 1, 1991  BH Négrier et al., "Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internat Medicine, 114:7 April 1, 1991  BH Négrier et al., "Intensive Regimen of Cytokines with Interleukin-2 and Interferon Alfa-28 in Selected Patients with Metastatic Renal Carcinome," Journal of Immunotherapy, 17:62-68 1995  BI Goldman, "Opimizing Treatment for Dororic Myeloid Leukemia," The New England Journal of Medicine," 337:4, pp. 270-271, July 24, 4997  BJ Guilhot, et al., "Interferon Alfa-2b Cymptined with Cytarabine Versus Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Interferon Alfa-2 and Interferon Alfa-2 in Propessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13: 2 pp. 497-501 February, 1995  BK Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp.7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-alba human malignancies," The Lancet, 335 pp	l	00	
BD Fleming et al., "One-Sample Multiplel Testing Procedure for Pkáse II Clinical Trials," Biometrics 38:143-151 March 1982  BE Rosenberg, et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989  BF Kantarjian et al., "Prolonged Survical in Chronic Myelogenouos Leukemia after Cytogenetic Response to Interferon-α Therapy." Ann Interm Med/122:254-261, 1995  BG Talpaz et al., "Interferon-Alpha Produces Suskáined Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Interna Med/122:254-261, 1995  BH Négrier et al., "Interferon-Alpha Produces Suskáined Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Interna Medicine, 1347-4 April 1, 1991  BH Négrier et al., "Interferon-Alpha Produces Suskáined Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Interna Medicine, 1374-2 April 1, 1991  BJ Goldman, "Optimizing Treatment for Optoric Myeloid Leukemia," The New England Journal of Medicine, 337-4, pp. 270-271, July 23, 1997  BJ Guilhot, et al., "Interferon Alfa-2 be dymβrined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The New England Journal of Medicine, 337-4 pp. 223-229  BK The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "The New England Journal of Medicine, 337-4 pp. 223-229  BL Atzpodien et al., "Miltimistitujúnal Home-Therapy Trial of Recombinant Human Interieukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13: 2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp.7-17, January 1996  BN Atzpodiene tal., "Mome therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignaricies," The Lancet, 335 pp. 1509-1512, 1999  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRO		50	September 13, 136
BD Fleming et al., "One-Sample Multiplet Testing Procedure for Phase II Clinical Trials," Biometrics 38:143-151 March 1982  BE Rosenberg, et al., "Experience with the Use of High-Dose interleukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989  BF Kantarjian et al., "Prolonged Survical in Chronic Myelogenouos Leukemia after Cytogenetic Response to Interferon-α Therapy," Ann Intern Med. 122:254-261, 1995  BG Talpaz et al., "Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Interhal Medicine, 114:7 April 1, 1991  BH Négrier et al., "Intersive Regimen of Cytokines," with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinome." Journal of Immunotherapy, 17:62-68 1995  BI Goldman, "Optimizing Treatment for (Dropic Myeloid Leukeemia," The New England Journal of Medicine," 337:4, pp. 270-271, July 23, 1997  BJ Guilhot, et al., "Interferon Alfa-2b Gombined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Interferon Alfa-2 as as Compared with Conventional," Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, "330:12 pp. 820-825, March 24, 1994  BL Atzpodien et al., "Multinstitutional Home-Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 13: pp. 71-71, January 1995  BN Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp.71-71, January 1995  BN Alfonso Genpfaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BO Alfonso Genpfaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BO Alfonso Genpfaro, "Antineoplastic Renal Cell Carcinoma (MRCC),"	1	BC	Sokal et al., Preferential Infibition by Cytarabile of Crossiv Floyin Automotive Crossiv Floyin Automotive Crossiv Floyin Automotive Crossiv Floyin Automotive Crossiv Floying
BE Rosenberg, et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989  BF Kantanjian et al., "Prolonged Survical in Chronic Myelogenouos Leukemia after Cytogenetic Response to Interferon-A Therapy," Ann Intern Med, 122:254-261, 1995  BG Talpaz et al., "Interferon-Alpha Produces Suskined Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Interhal Myeloicen, 114:7 April 1, 1991  BH Negrier et al., "Intensive Regimen of Cytokines with Interleukin-2 and Interferon Alfa-2 in Selected Patients with Metastatic Renal Carcinome," Journal of Immunotherapy, 17:62-68 1995  BI Goldman, "Optimizing Treatment for Deforic Myeloid Leukemia," The New England Journal of Medicine," 337:4, pp. 270-271, July 24, 4997  BJ Guilhot, et al., "Interferon Alfa-2 Cytogenous Leukemia," The New England Journal of Medicine, 337:4, pp. 270-271, July 24, 4997  BK The Italian Cooperative Study Chronic Myeloid Leukemia, "The New England Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Chronic Myeloid Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229  BL Alzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1996  BM Kirkwood et al., "Huterferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14:1 pp./7-17, January 1996  BN Alzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-alze in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BP Bukowski," "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patiense with Solid Tumors," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLC Creey Trial: Interleukin-2 and Interferon (IFN)			Granulocytic Leukemia, Cancer 59:197-202, January 1, 1907
BE Rosenberg, et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989  BF Kantarjian et al., "Prolonged Survical in Chronic Myelogenouos Leukemia after Cytogenetic Response to Interferon-α Therapy," Ann Intern Medicine, 114:7 April 1, 1991  BG Talpaz et al., "Interferon-Alpha Produces Suskined Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Interlad Medicine, 114:7 April 1, 1991  BH Negrier et al., "Interieron-Regimen of Cytokines with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinome," Journal of Immunotherapy, 17:62-68 1995  BI Goldman, "Optimizing Treatment for Dionic Myeloid Leukeemia," The New England Journal of Medicine," 337:4, pp. 270-271, 13th 24, 1991  BJ Guilhot, et al., "Interferon Alfa-2b Complined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The NewEngland Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, 330:12 pp. 820-825, March 24, 1994  BL Atzpodien et al., "Multiinistitui/onal Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14:1 pp/7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BP Bukowski," Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-28 (PEG INTRON) in Patient-with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract No. 628, 15:248, March 1996  BRI	1	BD	
Cancer Patients," Ann. Surg. 210:4 pp. 474-485, 1989  BF Kantarjian et al., "Prolonged Survical in Chronic Myelogenouos Leukemia after Cytogenetic Response to Interferon-α Therapy," Ann Intern Med. 122:254-261, 1995  BG Talpaz et al., "Interferon-Alpha Produces Suskingd Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Internal Myelicine, 114:7 April 1, 1991  BH Négrier et al., "Intensive Regimen of Cytokines with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinomg." Journal of Immunotherapy, 17:62-68 1995  BI Goldman, "Optimizing Treatment for Quoride Myeloid Leukeemia," The New England Journal of Medicine," 337:4, pp. 270-271, July 24, 1997  BJ Guilhot, et al., "Interferon Alfa-2b Combined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The New England Journal of Medicine, 337:4, pp. 223-229  BK The Italian Cooperative Study Chroy on Chronic Myeloid Leukemia, "The New England Journal of Medicine," 330:12 pp. 820-825, March 24, 1994  BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14:1 pp./7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BN Affonso Gengiaro, "Antineoplastic and immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BN Affonso Gengiaro, "Antineoplastic and immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BRI Deprés-Brummer et al., "A Phase IT Tyddy of Ambulatory Chronomodulated High Dose Interferon (IFNo2a) Against Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BRI			38:143-151 March 1982
BF Kantarjian et al., "Prolonged Survical in Chronic Myelogénouos Leukemia after Cytogenetic Response to Interferon-α Therapy," Ann Intern Med, "22:243-261, 1995  BG Talpaz et al., "Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Internal Myelodicine, 114:7 April 1, 1991  BH Négrier et al., "Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internal Myelodicine, 114:7 April 1, 1991  BI Goldman, "Optimizing Treatment for Deroyide Myeloid Leukeemia," The New England Journal of Medicine," 337:4, pp. 270-271, July 24, 1997  BJ Guilhot, et al., "Interferon Alfa-2b Gomplined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The NewEngland Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Groyfo on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventional, Chromotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine," 330:12 pp. 820-825, March 24, 1994  BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14:1 pp./*1-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BN Alfonso Gendaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patisark-with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN)	J	BE	Rosenberg, et al., "Experience with the Use of High-Dose thterleukin-2 in the Treatment of 652
BF Kantarjian et al., "Prolonged Survical in Chronic Myelogénouos Leukemia after Cytogenetic Response to Interferon-α Therapy," Ann Intern Med, "22:243-261, 1995  BG Talpaz et al., "Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Internal Myelodicine, 114:7 April 1, 1991  BH Négrier et al., "Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Internal Myelodicine, 114:7 April 1, 1991  BI Goldman, "Optimizing Treatment for Deroyide Myeloid Leukeemia," The New England Journal of Medicine," 337:4, pp. 270-271, July 24, 1997  BJ Guilhot, et al., "Interferon Alfa-2b Gomplined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The NewEngland Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Groyfo on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventional, Chromotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine," 330:12 pp. 820-825, March 24, 1994  BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14:1 pp./*1-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BN Alfonso Gendaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patisark-with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN)	ļ		Cancer Patients," Ann. Surg. <b>210</b> :4 pp. 474-485, 1989 /
Response to Interferon-α Therapy," Ann Intern Med/12:254-261, 1995  BG Talpaz et al., "Interferon-Alpha Produces Sustáined Cytogenetic Responses in Chronic Myelogenouos Leukemia," Annals of Internal Medicine, 114:7 April 1, 1991  BH Négrier et al., "Intensive Regimen of Cytokyhes with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinomg." Journal of Immunotherapy 17:62-68 1995  BI Goldman, "Optimizing Treatment for Deroylic Myeloid Leukeemia," The New England Journal of Medicine," 337:4, pp. 270-271, July 24, /997  BJ Guilhot, et al., "Interferon Alfa-2b Gombined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, "330:12 pp.820-825, March 24, 1994  BL Atzpodien et al., "Multiinsitiut/fonal Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp./7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignaficies," The Lancet, 335 pp. 1509-1512, 1990  BO Alfonso Genpáro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patiente with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  BRI Deprés-Brummer et al., "A Phase IT Sudy of Ambulatory Chronomodulated High Dose Interferon (IFNo2a) Against Metastatic Renal Cell (Carcinopta, The UCLA Kidney Cancer Program," American Soc		BF	Kantarijan et al., "Prolonged Survical in Chronic Myelogenouos Leukemia after Cytogenetic
BG   Talpaz et al., "Interferon.Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia," Annals of Interhag Medicine, 114:7. April 1, 1991			Response to Interferon-α Therapy," Ann Intern Med 122:254-261, 1995
Myelogenouos Leukemia," Annals of Internat Medicine, 114:7 April 1, 1991   BH Négrier et al., "Intensive Regimen of Cytokihes with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinome," Journal of Immunotherapy, 17:62-68 1995   Bi Goldman, "Optimizing Treatment for Obforic Myeloid Leukemia," The New England Journal of Medicine," 337:4, pp. 270-271, July 24, 1997   BJ Guilhot, et al., "Interferon Alfa-2b Complined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229   BK The Italian Cooperative Study Grodp on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventional Chromotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine," 330:12 pp. 820-825, March 24, 1994   BL Atapodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 Februay 1995   BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14:1 pp/7-17, January 1996   BN Atapodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignañcies," The Lancet, 335 pp. 1509-1512, 1990   BO Alfonso Gennaro, "Antineoplastic and Immunoactive Drugs," Remington's 18" Ed., 1990   BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patients with Solid Tumors," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996   BR1		BC.	Talpaz et al. "Interferon Alpha Produces Sustained Cytogenetic Responses in Chronic
BH Négrier et al., "Intensive Regimen of Cytokihes" with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Carcinomes, "Journal of Immunotherapy, 17:62-68 1995  BI Goldman, "Optimizing Treatment for Obronic Myeloid Leukeemia," The New England Journal of Medicine," 337:4, pp. 270-271, July 24, 4997  BJ Guilhot, et al., "Interferon Alfa-2b Complined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Grodp on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventiohal, Chrimotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine," 330:12 pp. 820-825, March 24, 1994  BL Atzpodien et al., "Multiinstitujónal Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessíve Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14:1 pp./7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patiente with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  BC Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Study of Ambulatory Chronomodulated High Dose Interferon (IFNα/2a) Against Metastatic Renal/Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC/Crecy Trial: Interleukin 2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma (MRCC)," American Society		BG	Myclocopeus Leukomia " Annals of Internal Medicine 114.7 April 1 1991
Patients with Metastatic Renal Carcinoms." Journal of Immunotherapy, 17:62-68 1995  BI Goldman, "Optimizing Treatment for Obroric Myeloid Leukeemia," The New England Journal of Medicine," 337:4, pp. 270-271, July 24, 4997  BJ Guilhot, et al., "Interferon Alfa-2b Combined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine, 330:12 pp.820-825, March 24, 1994  BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp/-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patienewith Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase Il Tyddy of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal/Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "F		5	Myerogenous Leurenina, Animais of Cytokinoguith Interlouking 2 and Interferon Alfa-28 in Selected
Bil   Goldman, "Optimizing Treatment for Chronic Myeloid Leukeemia," The New England Journal of Medicine," 337:4, pp. 270-271, Juny 24, /997	•	BH	Negrier et al., intensive Regiliner of Cytokines with interfecting and interfection Alaza in Colonia
Medicine," 337.4, pp. 270-271, JMy 24, 1997	<u> </u>		Patients with inetastatic Renai Carcinoma, Journal of Infilitinomerapy, 17.02-06 1995
BJ Guilhot, et al., "Interferon Alfa-2b Combined with Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine," 330:12 pp.820-825, March 24, 1994  BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp./7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BO Alfonso Genziaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patisarke with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Fludy of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal/Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropy Midines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma (MRCC)," American Soc		l BI	Goldman, "Optimizing Treatment for Opropic Myelold Leukeemia, The New England Journal of
Myelogenous Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229  BK The Italian Cooperative Study Croup on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine," 330:12 pp. 820-825, March 24, 1994  BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp./7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BO Alfonso Gennaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patients with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropy Indidnes Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BR5 Gitlitz et al., "Randomised Study Usin			Medicine," 337:4, pp. 270-271, July 24, 1997
BK The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine," 330:12 pp.820-825, March 24, 1994  BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp./7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BO Alfonso Genraro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patient with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  BQ Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Yudy of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March/1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropythidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma." The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BR5 P. Sagaste, et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cime	1	BJ	Guilhot, et al., "Interferon Alfa-2b Combined with Cytarabine Versus Interferon Alone in Chronic
Compared with Conventional Chémotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine," 330:12 pp.820-825, March 24, 1994  BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp. 7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BO Alfonso Genráro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patiente with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  BQ Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IF Yudy of Ambulatory Chronomodulated High Dose Interferon (IFNo2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropy findines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinomia. The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus courarin and cimetidine for treatment of Advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  D.	<b>;</b>		Myelogenous Leukemia," The New England Journal of Medicine, 337:4 pp. 223-229
Compared with Conventional Chémotherapy for the Treatment of Chronic Myeloid Leukemia," The New England Journal of Medicine," 330:12 pp.820-825, March 24, 1994  BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp. 7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BO Alfonso Genráro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patiente with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  BQ Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IF Yudy of Ambulatory Chronomodulated High Dose Interferon (IFNo2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropy findines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinomia. The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus courarin and cimetidine for treatment of Advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  D.		BK	The Italian Cooperative Study Group on Chronic Myeloid Leukemia, "Interferon Alfa-2a as
New England Journal of Medicine," 330:12 pp.820-825, March 24, 1994	;		Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia," The
BL Atzpodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14:1 pp./7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-\(\alpha\)2 bin advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BO Alfonso Gennaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patients with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  BQ Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase Il Study of Ambulatory Chronomodulated High Dose Interferon (IFN\(\alpha\)2) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropy trividines Plus Interleukin-2 and Interferon-\(\alpha\) in the Treatment of Metastatic Renal Cell Carcinoma," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BR3 Gitlitz et al., "Randomised Study Using IFN-\(\alpha\) versus IFN-\(\alpha\) plus coumarin and cimetidine for treatment of Agr/anced renal cel cancer," Annals of Oncology 6:999-1003, 1995  D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliabjity testing in large samples of patients with c	:		New England Journal of Medicine," 330:12 pp.820-825, March 24, 1994
Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology, 13:2 pp. 497-501 February 1995  BM Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp. 7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BO Alfonso Gennaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patients with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropy indicines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BR5 P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of Advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliabjity testing in large samples of patients with cancer," Quality of Life Research 6:103-	i	BI	Atzoodien et al., "Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and
13:2 pp. 497-501 February 1995	į.	"-	Interferon Alfa-2 in Progessive Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology,
BM   Kirkwood et al., "Interferon Alfa-2b Adjuvant Therapy of High-Rish Resected Cutanenous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14: 1 pp. 7-17, January 1996	i		13:2 pp. 497-501 February 1995
Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," Journal of Clinical Oncology, 14:1 pp/7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BO Alfonso Gennaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patiente-with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropy indines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of devanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliably ty testing in large samples of patients with cancer," Quality of Life Research 6:103-		DM.	Kirkwood et al. "Interferon Alfa-2h Adjuvant Therapy of High-Rish Resected Cutanenous
Oncology, 14: 1 pp/7-17, January 1996  BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BO Alfonso Genraro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patients with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  BQ Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase Il Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Creey Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropy Indidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinomia (MRCC)," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al. "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of Ladvanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-	}	Divi	Molanoma: The Fastern Cooperative Oncolony Group Trial FST 1684." Journal of Clinical
BN Atzpodien et al., "Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies," The Lancet, 335 pp. 1509-1512, 1990  BO Alfonso Gennaro, "Antineoplastic and Immunoactive Drugs," Remington's 18 <sup>th</sup> Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patiente with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  BQ Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropyrindidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinomy and Cell Carcinomy	1		Oppology 44:1 pp 7-17 January 1996
Numan malignancies," The Lancet, 335 pp. 1509-1512, 1990	· · · · · ·	DNI	Officiology, 14. 1 pp: 7-17, bandary 1999
BO Alfonso Genaro, "Antineoplastic and Immunoactive Drugs," Remington's 18" Ed., 1990  BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patients with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropy indidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinomia (The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-	ŧ	BIA	Atzpodien et al., Home therapy with recombinant interleuturi-z and interleuturi-dzb in advanced
BP Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in Patients with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropyrinidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma. The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-	1	<u> </u>	human malignancies," The Lancet, 335 pp. 1509-1512, 1990
Patients with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  RO Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropyrinidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma. The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-		BO	Alfonso Gengaro, "Antineoplastic and Immunoactive Drugs," Remington's 18" Ed., 1990
Patients with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract  RO Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropyrinidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma. The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-			
BQ Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gittlitz et al., "Fluoropyrinidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma." The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of Jacvanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-	, , ,	BP	Bukowski, "Phase 1 Study of Polyethylene Glycol (PEG) Interferon Alpha-2B (PEG INTRON) in
BQ Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme," The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase II Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropyrinidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma." The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of Advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-		]	Patients with Solid Tumors," American Society of Clinical Oncology, 1999 Abstract
The Lancet, 343:913-914 April 9, 1994  BR1 Deprés-Brummer et al., "A Phase IT Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropyrindidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma. The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-	ia - 1 - 1	BQ	Cascinelli, N. et al., "Results of adjuvant interferon study in WHO melanoma programme,"
BR1 Deprés-Brummer et al., "A Phase IT Study of Ambulatory Chronomodulated High Dose Interferon (IFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropyrinidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma. The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-	I KVK		
CIFNα2a) Against Metastatic Renal Cancer (MRC)," American Society of Clinical Oncology, Abstract No. 628, 15:248, March 1996    BR2	<u> </u>	BR1	Deprés-Brummer et al "A Phase IT Wildy of Ambulatory Chronomodulated High Dose Interferon
Abstract No. 628, 15:248, March 1996  BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropyrimidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma. The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-	١ ٨٠	١٠٠٠	(IENG2a) Against Metastatic Renal Cancer (MRC) "American Society of Clinical Oncology.
<ul> <li>BR2 Escudier et al., "The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996</li> <li>BR3 Gitlitz et al., "Fluoropyrimidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma." The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996</li> <li>BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995</li> <li>BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-</li> </ul>	1 HUM	1	
Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC)," American Society of Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropyrimidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinoma." The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-		BC2	Franction et al. "The ENCLOC Cropy Trial: Interleukin 2 (II 2) + Interferon (IFN) is the Ontimal
Clinical Oncology, Abstract No. 629, 15:248, March 1996  BR3 Gitlitz et al., "Fluoropyrimidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinopha. The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-	1	BK2	ESCUDIER et al., The PNOLOGORECY That Interieural 2 (122) + Interieron (in try is the Optimal
BR3 Gitlitz et al., "Fluoropyrimidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic Renal Cell Carcinopha. The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-		l	
Renal Cell Carcino ha. The UCLA Kidney Cancer Program," American Society of Clinical Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-		<u> </u>	Clinical Oncology, Abstract No. 629, 15:248, March 1996
Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-		BR3	Gitlitz et al., "Fluoropyrimidines Plus Interleukin-2 and Interferon-α in the Treatment of Metastatic
Oncology, Abstract No. 630, 15:248, March 1996  BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-	! !		Renal Cell Carcinothat The UCLA Kidney Cancer Program," American Society of Clinical
BS P. Sagaster et al., "Randomised Study Using IFN-α versus IFN-α plus coumarin and cimetidine for treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-		1	Oncology, Abstract No. 630, 15:248, March 1996
treatment of advanced renal cel cancer," Annals of Oncology 6:999-1003, 1995  BT D. Osoba, et al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-	<u> </u>	BS	
D. Osoba, et/al., "Modification of the EORTC QLQ-C30 (version 2.0) based onn content validity and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-	li	1	treatment of advanced renal cel cancer." Annals of Oncology 6:999-1003, 1995
and reliability testing in large samples of patients with cancer," Quality of Life Research 6:103-	<del>  \</del>	DT.	D. Osoba, et/al. "Modification of the FORTC QLO-C30 (version 2.0) based onn content validity
	Ι \ ,	"	and reliability testing in large samples of natients with cancer " Quality of Life Research 6:103-
1 100,1984			
	L	<u></u>	100,19962

me i Hollian

5/17/2003

Sheet	3	of	3
	_	<b>U</b> :	_

FORM	PTO-1	1449

## U.S. BEPARTMENT OF COMMERCE

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

	ATTY. DOCKET NO.:	SERIAL NO.:
	OCO1000KQ	09/904,263
ĺ	APPLICANT:	
į	Rybak et al.	
	FILING DATE:	GROUP:
	July 12, 2001	1642

BU Sewa S. Legha, "The Role of Interferon Alfa in the Treatment of Metastatic Melanoma," S						
1 1/2 /	1	in Oncology, <b>24</b> :1 Suppl 4 (February) 1997, pp. S4-24-54-31				
1	BV	W. Levens et al., "Long-Term Interferon Treatment in Metastatic Renal Cell Carcinoma," Eur Urol	I.			
		<b>16</b> :378-381, 1989				
	BW	Janice P. Dutcher, et al., "Outpatient Subcutaneous Interleukin-2 and Interferon-Alpha for				
l i	1	Metastatic Renal Cell Cancer: Five-Year Follow-up of the Cytokine Working Group Study," The				
1		Cancer Journal from Scientific Américan 3:3 May/June 1997				
	ВХ	Talpaz et al, "Phase I Study Of Polyéthylene Glycol (PEG) Interferon Alpha-2B (Intron-A) in CML				
1		Patients", Blood, Volume 92, Iskue 10, Suppl. 1 part 1-2, 11/15, 1998, pp. 251A				
	BY	Talpaz et al, "Phase I Study of Pegylated-Interferon α-2A (PEGASYS™) In Patients With Chronic	;			
1		Myelogenous Leukemia (CML)", Blood, Vol. 94, Issue 10, Suppl. 1, part 1, 11/15, 1999, pp.530A.				
	BZ	Walther P.J. et al. "Treatment of Metastatic Renal Cell Carcinoma (RCC) with Continuous Infusio	on			
1 1		5-Fluorouracil and hyterferon Alpha-2A in the Home Setting: A Phase I-II Trial", Proceedings of the	e			
1 1		American Urological Association, Vol. 155, May 1996 Supplement, p. 388A.				
	CA	Gebrosky et al., "Treatment of Renal Cell Carcinoma with 5-Fluorouracil and Alfa-Interferon",				
		Urology, 50 (6) 1997, pp. 863-868.				
1 1						
	СВ	Atzpodien J. et al., "Interleukin-2 in Combination with Interferon-α and 5-Fluorouracil for Metastati	ic			
1 1.		Renal Cell Cancer", European Journal of Cancer, Vol. 29A, Suppl. 5, 1993, pp. S6-S8.				
$\cup$						
Only	СМ	Bukowski et al., "Pegylated Interferon Alfa-2b Treatment for Patients with Solid Tumors: A	k.			
my		Phase I/II Study," J. Clin. Oncol. 20 (18) 3841-3849 (2002).				
EXAMINER DATE CONSIDERED						
EXAMINER DATE CONSIDERED 5/17/2003						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line						
through c	through citation if not in conformance and not considered. Include copy of this form with next communication to					

29132\_1

applicant.

RECEIVED

MAR 1 0 2003

TECH CENTER 1600/2900